Andarine S4 — 25 mg/capsule · 60 capsules
25 mg/capsule · 60 capsules
No disponible actualmente
NovaMeds
This research bundle combines three synthetic compounds frequently studied together in selective receptor and metabolic pathway research: S4 (Andarine), a synthetic research molecule studied for selective molecular pathway interactions; S-23, studied for specific receptor binding properties; and GW-501516 (Cardarine), studied for metabolic pathway modulation.
Presentación: S23 + S4 + GW-501516 Value Pack.
Envase ilustrativo generado con IA.
No apto para uso humano o veterinario.
This research bundle combines three synthetic compounds frequently studied together in selective receptor and metabolic pathway research: S4 (Andarine), a synthetic research molecule studied for selective molecular pathway interactions; S-23, studied for specific receptor binding properties; and GW-501516 (Cardarine), studied for metabolic pathway modulation.
Combined research models allow investigation into how multiple selective receptor compounds and a metabolic modulator may intersect within body composition and metabolic efficiency research. Research applications include comparative selective receptor pathway studies and multi-compound metabolic research design.
| Synonyms | S4 + S23 + GW-501516 Value Pack |
|---|---|
| Shelf Life | 36 months |
This value pack pairs S4 (Andarine), a synthetic research molecule designed for investigating selective molecular pathways, with S-23, a selective non-steroidal compound studied for specific receptor binding properties in laboratory models, and GW-501516 (Cardarine), a research compound studied for metabolic pathway modulation including glucose transport and lipid metabolism research. Combined research protocols examining all three compounds allow investigation into how two structurally distinct selective receptor modulators and a metabolic pathway compound may interact within multi-pathway body composition and metabolic efficiency research models. Each compound is independently third-party HPLC-tested; COA available per batch.
S4 (Andarine) and S-23 are both studied for selective receptor binding properties but represent structurally distinct compounds within this research category, allowing comparative research into how subtle structural differences influence receptor selectivity and downstream pathway engagement when studied within the same experimental protocol.
Cell-based receptor binding and selectivity assays, alongside metabolic flux measurements (such as glucose uptake and lipid oxidation assays) for the GW-501516 component, are standard methods for studying this combination, typically compared across single-compound and combined-compound treatment arms.
Factorial or staggered experimental designs incorporating single-compound, paired-compound, and full three-compound treatment arms allow researchers to isolate the contribution of each compound and identify any combination-specific effects on selected receptor and metabolic research endpoints.